BenkertPMeierSSchaedelinS, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol2022; 21(3): 246–257.
2.
DisantoGBarroCBenkertP, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2017; 81: 857–870.
3.
BarroCBenkertPDisantoG, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain2018; 141: 2382–2391.
4.
SotirchosESHuCSmithMD, et al. Agreement between published reference resources for neurofilament light chain levels in people with multiple sclerosis. Neurology2023; 101: e2448–e2453.
5.
RotsteinDMontalbanX.Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol2019; 15(5): 287–300.
HardingKWilliamsOWillisM, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol2019; 76: 536–541.
8.
HeAMerkelBBrownJWL, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol2020; 19(4): 307–316.
9.
StankiewiczJMWeinerHL.An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2019; 27(1): e636.
10.
AbdelhakAFoschiMAbu-RumeilehS, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol2022; 18(3): 158–172.
